Eledon Pharmaceuticals Inc expected to post a loss of 30 cents a share - Earnings Preview
05/05/2025 14:32
Eledon Pharmaceuticals Inc ELDN.OQ ELDN.O is expected to show no change in quarterly revenue when it reports results on May 7 (estimated) for the period ending March 31 2025 ‚ÄčLSEG's mean analyst estimate for Eledon Pharmaceuticals Inc is for a loss of 30 cents per share. The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The mean earnings estimate of analysts had fallen by about 11.2% in the last three months. ‚Äč Wall Street's median 12-month price target for Eledon Pharmaceuticals Inc is $9.00‚Äč, above‚Äč its last closing price of $3.31. ‚Äč‚Äč‚Äč Previous quarterly performance (using preferred earnings measure in US dollars). ‚Äč
| QUARTER ENDING | STARMINESMARTESTIMATE¬ģ | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
| Dec. 31 2024 | -0.31 | -0.32 | 0.67 | Beat | 310.7 |
| Sep. 30 2024 | -0.20 | -0.31 | -0.32 | Missed | -1.6 |
| Jun. 30 2024 | -0.29 | -0.30 | -1.06 | Missed | -249.4‚Äč |
| Mar. 31 2024 | -0.36 | -0.37 | -0.34 | Beat | 7 |
| ‚Äč‚ÄčDec. 31 2023 | -0.39 | -0.29 | Beat | 26 | |
| Sep. 30 2023 | -0.50 | -0.46 | -0.35 | Beat | 24‚Äč |
| Jun. 30 2023 | -0.46 | -0.46 | -0.40 | Beat | 12.8 |
| Mar. 31 2023 | -0.58 | -0.60 | -0.75 | Missed | -25.2 |
Recent news on Eledon Pharmaceuticals
See all newsBrief: Eledon Presents Updated Long-Term Phase 2 Bestow Extension Study Results At The International Congress Of The Transplantation Society
Eledon Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary
Eledon Pharmaceuticals Q2 net loss widens on warrant liability changes
Eledon Pharmaceuticals Inc expected to post a loss of 16 cents a share - Earnings Preview
Brief: Natera And Eledon Announce Strategic Partnership For Prospera™ Monitoring In Planned Phase 3 Kidney Transplant Trial